Opioid use disorder, pharmacotherapy, and overdose among Medicare disability beneficiaries from 2008-2021
- 1 June 2026
- journal article
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 72 (1) , 108455
Abstract
No abstract availableKeywords
Funding Information
- Intramural Research Program (K99DA057372)
- Intramural Research Program (R01DA057568)
- Intramural Research Program (K01DA049950)
- Intramural Research Program (R01DA047347)
- National Institute on Drug Abuse
- Pew Charitable Trusts
- National Center for Advancing Translational Sciences (UL1TR003017)
This publication has 56 references indexed in Scilit:
- Trends in Access to Medications for Opioid Use DisorderJAMA Health Forum, 2025
- Associations Between Annual Medicare Part D Low-Income Subsidy Loss and Prescription Drug Spending and UseJAMA Health Forum, 2024
- Patterns in Geographic Distribution of Substance Use Disorder Treatment Facilities in the US and Accepted Forms of Payment From 2010 to 2021JAMA Network Open, 2022
- Factors Associated With Opioid Overdose After an Initial Opioid PrescriptionJAMA Network Open, 2022
- Association of Racial/Ethnic Segregation With Treatment Capacity for Opioid Use Disorder in Counties in the United StatesJAMA Network Open, 2020
- Trends in Buprenorphine Treatment in the United States, 2009-2018JAMA, 2020
- Association of Disability With Mortality From Opioid Overdose Among US Medicare AdultsJAMA Network Open, 2019
- Association Between Medicare and FDA Policies and Prior Authorization Requirements for Buprenorphine Products in Medicare Part D PlansJAMA, 2019
- Limiting the Duration of Opioid PrescriptionsJAMA Internal Medicine, 2016
- CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016JAMA, 2016